FibriCheck vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

FibriCheck

by Qompium nv

EchoNext

by Pathway Labs

AI Verdict

FibriCheck and EchoNext are adjacent tools in cardiology AI, both focusing on heart health but with distinct approaches. FibriCheck is designed for remote monitoring of heart rhythms to detect arrhythmias using a smartphone camera, while EchoNext analyzes standard ECGs to detect hidden structural heart disease. Therefore, FibriCheck is better suited for ongoing rhythm monitoring, whereas EchoNext is for diagnostic support in identifying underlying structural issues.

Choose FibriCheck if…

Choose FibriCheck if you need a convenient, patient-centric solution for continuous heart rhythm monitoring and arrhythmia detection using a smartphone. It's ideal for early detection of irregular heart rhythms, investigating palpitations, monitoring patients after cardiac procedures, and managing existing heart rhythm conditions remotely between clinic visits.

View FibriCheck →

Choose EchoNext if…

Choose EchoNext if you require an AI-powered tool to analyze standard ECGs for the detection of hidden structural heart disease, such as heart failure, valve disease, and pulmonary hypertension. This tool is best suited for broad screening in various clinical settings, from major hospitals to community practices, to identify high-risk patients who may require further diagnostic imaging like echocardiograms.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	FibriCheck	EchoNext
Pricing	Available via subscription for end-users (monthly/yearly) or through licensing agreements for healthcare providers and clinical centers.	Starts at $600/month
Deployment	Cloud-based digital application	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

FibriCheck

FibriCheck is designed for ease of use by patients, requiring only a smartphone camera for measurements and providing immediate, actionable results. Multiple sources highlight its intuitive design and high user satisfaction, making it highly accessible for remote monitoring. EchoNext, while offering a non-invasive diagnostic, is integrated into a clinical decision support platform, suggesting its primary users are healthcare professionals rather than patients directly.

Clinical Value

EchoNext

EchoNext offers significant clinical value by detecting hidden structural heart disease from standard ECGs, conditions that often go undiagnosed until symptomatic. Studies show it outperforms cardiologists in accuracy and has led to earlier diagnoses and interventions, including heart transplants. FibriCheck provides valuable arrhythmia detection and monitoring, but EchoNext's ability to identify previously undetectable structural heart disease represents a more profound diagnostic advancement.

Pricing & Value

FibriCheck

FibriCheck offers transparent tiered pricing for end-users and licensing for healthcare providers, with monthly/yearly subscriptions and optional expert reviews. It also highlights potential reimbursement options in several countries. EchoNext's pricing starts at a higher monthly rate and is tiered for institutions, with an additional implementation fee, making its cost less transparent and potentially less accessible for individual practitioners or smaller organizations.

Enterprise Readiness

Tie

Both tools demonstrate enterprise readiness. FibriCheck offers a healthcare professional portal, customizable monitoring rules, API-based integration into EHRs, and supports remote patient monitoring billing. EchoNext is deployed through the OpenEvidence clinical decision support platform, used by a large number of US physicians, and has been validated across multiple health systems, indicating its scalability and integration capabilities within existing clinical workflows.

Innovation

EchoNext

EchoNext represents a significant innovation by being the first FDA-approved AI tool to detect hidden structural heart disease from standard ECGs, a capability previously unavailable. This addresses a critical gap in early detection for conditions like heart failure and valve disease. While FibriCheck's smartphone-based PPG technology is innovative for remote arrhythmia monitoring, EchoNext's diagnostic breakthrough for structural heart disease is arguably more impactful.

Support & Docs

FibriCheck

FibriCheck provides a comprehensive help center with sections for individuals, healthcare providers, and partners, including FAQs, educational materials, and user manuals. This structured approach to documentation and support resources makes it easier for various user groups to find the information they need. Information regarding EchoNext's specific support and documentation beyond its deployment platform is not as readily available.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	FibriCheck	EchoNext
Name	FibriCheck	EchoNext
Company	Qompium nv	Pathway Labs
Description	FibriCheck is a medically certified app that helps patients monitor their heart rhythm to detect and monitor arrhythmias using just their smartphone.	EchoNext is an FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Key Functionality	Smartphone camera-based PPG technology for heart rhythm measurement, AI-powered algorithm for arrhythmia detection and analysis, healthcare professional portal/dashboard for patient monitoring, patient-facing mobile application, detection of Atrial Fibrillation (AFib) and other arrhythmias, immediate and actionable results, ability to log blood pressure and weight, customizable monitoring rules for healthcare providers.	AI-powered ECG analysis, detection of hidden structural heart disease, identifies heart failure risk, screens for valve disease, detects pulmonary hypertension indicators, utilizes standard 12-lead ECGs, FDA-cleared technology, non-invasive diagnostic support.
Specialties	Cardiology, Family Medicine, Internal Medicine	Cardiology, Family Medicine, Hospital Medicine, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring FibriCheck and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

FibriCheck is designed for seamless integration into existing clinical workflows, offering structured data for review and reporting, and API-based integration into EHRs, RPM platforms, and population health systems. EchoNext integrates with the OpenEvidence clinical decision support platform, which is used by many physicians, allowing its screening outputs to be embedded directly into common clinical workflows without requiring a separate system.

What is the accuracy and sensitivity of each tool in detecting cardiac conditions?

FibriCheck demonstrates high overall performance in detecting Atrial Fibrillation (AF), with an accuracy of 98.5%, sensitivity of 96.3%, and specificity of 99.3%. EchoNext, trained on over a million ECG-echocardiogram pairs, achieved an AUROC of 85% in internal tests and 78-80% in external validation for detecting structural heart disease. In a head-to-head comparison, EchoNext accurately identified 77% of structural heart problems, outperforming cardiologists who had an accuracy of 64%.

For which specialties are these tools best suited, and what clinical context supports their use?

FibriCheck is well-suited for cardiology, family medicine, and internal medicine, particularly for early detection and longitudinal monitoring of arrhythmias like AF, managing palpitations, and post-procedure follow-up. EchoNext is designed for cardiology, family medicine, hospital medicine, and internal medicine, serving as a screening tool to identify patients who should be referred for an echocardiogram to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.

What is the typical learning curve for physicians and their staff to effectively use these tools?

FibriCheck is designed to be user-friendly for patients, who can be easily trained to use the app. The frequency of measurements with insufficient quality for analysis decreased significantly during a screening period, indicating a steep learning curve for patients. EchoNext is integrated into the OpenEvidence platform, which many physicians already use, suggesting a potentially lower learning curve for integrating the AI's output into existing practices.

What audit-trail features do these tools offer for patient data and clinical decision-making?

FibriCheck provides clinical reports with summarized rhythm strips and insights into AF load and symptom correlation, with structured data available for clinical review. It also allows for the export of structured, EHR-compatible reports designed to support compliance and billing workflows. The system allows for custom monitoring rules, alert thresholds, and escalation triggers, which can be configured and reviewed in a provider portal.